MaxCyte Stock Price, News & Analysis (LON:MXCT)

GBX 241.40 3.40 (1.43 %)
(As of 01/18/2018 04:00 PM ET)
Previous CloseGBX 241.40
Today's RangeGBX 238.80 - GBX 241.40
52-Week RangeGBX 185 - GBX 305
Volume2,900 shs
Average Volume14,078 shs
Market Capitalization£139.38 million
P/E Ratio-2,414.00
Dividend YieldN/A

About MaxCyte (LON:MXCT)

MaxCyte logoMaxCyte, Inc. focuses on cell-based medicines. The Company's cell modification technology, Flow electroporation, is used for discovery, development and manufacture of small molecule, biologic and cell-based therapeutics. The Company's products include instruments, processing assemblies and insourcing services. Its instruments include systems, such as the MaxCyte STX, the MaxCyte VLX and the MaxCyte GT. The Company's MaxCyte GT Flow Transfection System, the MaxCyte STX Scalable Transfection System and the MaxCyte VLX Large Scale Transfection System enable the development and production of transfected cells for an array of applications. The Company offers a platform, which enables the engineering of a range of cells, including human primary cells. Its products are used in applications, including drug discovery, protein production and cell therapy. The Company offers messenger ribonucleic acid (mRNA) CAR T-cell based platform for immuno-oncology indications, including solid cancers.

Receive MXCT News and Ratings via Email

Sign-up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
SectorBio Therapeutic Drugs


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio-2414
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSGBX (0.10)
Net IncomeN/A
Net Margins-69.25%
Return on Equity-57.39%
Return on Assets-32.35%


Outstanding Shares43,560,000

MaxCyte (LON:MXCT) Frequently Asked Questions

What is MaxCyte's stock symbol?

MaxCyte trades on the London Stock Exchange (LON) under the ticker symbol "MXCT."

Where is MaxCyte's stock going? Where will MaxCyte's stock price be in 2018?

1 equities research analysts have issued twelve-month price targets for MaxCyte's shares. Their predictions range from GBX 338 to GBX 338. On average, they expect MaxCyte's stock price to reach GBX 338 in the next year. View Analyst Ratings for MaxCyte.

Who are some of MaxCyte's key competitors?

Who are MaxCyte's key executives?

MaxCyte's management team includes the folowing people:

  • Douglas A. Doerfler, President, Chief Executive Officer, Executive Director (Age 60)
  • Ronald E. Holtz CPA, Chief Financial Officer, Director (Age 50)
  • J. Stark Thompson Ph.D., Non-Executive Chairman of the Board (Age 69)
  • William W. Brooke, Non-Executive Director (Age 59)
  • Stanley C. Erck, Non-Executive Director (Age 68)
  • John J. Johnston, Non-Executive Director (Age 57)
  • Arthur M. Mandell, Non-Executive Director (Age 57)

How do I buy MaxCyte stock?

Shares of MaxCyte and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is MaxCyte's stock price today?

One share of MaxCyte stock can currently be purchased for approximately GBX 241.40.

How big of a company is MaxCyte?

MaxCyte has a market capitalization of £139.38 million.

How can I contact MaxCyte?

MaxCyte's mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The company can be reached via phone at +1-301-9441700.

MarketBeat Community Rating for MaxCyte (MXCT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  102
MarketBeat's community ratings are surveys of what our community members think about MaxCyte and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MaxCyte (LON:MXCT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 338GBX 338GBX 338GBX 338

MaxCyte (LON:MXCT) Consensus Price Target History

Price Target History for MaxCyte (LON:MXCT)

MaxCyte (LON:MXCT) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
9/19/2017Panmure GordonReiterated RatingBuyGBX 338View Rating Details
(Data available from 1/18/2016 forward)


Earnings History for MaxCyte (LON:MXCT)

No earnings announcements for this company have been tracked by


MaxCyte (LON:MXCT) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for MaxCyte (LON:MXCT)

No dividend announcements for this company have been tracked by

Insider Trades

MaxCyte (LON MXCT) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for MaxCyte (LON:MXCT)

MaxCyte (LON MXCT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/20/2016John JohnstonInsiderBuy37,500GBX 98£36,750
10/19/2016John JohnstonInsiderBuy37,500GBX 96£36,000
(Data available from 1/1/2013 forward)


MaxCyte (LON MXCT) News Headlines


SEC Filings

MaxCyte (LON:MXCT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.


Financials are not available for this stock.


MaxCyte (LON MXCT) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.